Crossmark

Adverse events associated with the use of cannabis-based products in people living with cancer: a systematic scoping review

Crossref DOI link: https://doi.org/10.1007/s00520-024-09087-w

Published Online: 2024-12-18

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cheah, Irene https://orcid.org/0009-0001-9288-4151
Hunter, Jennifer https://orcid.org/0000-0002-6109-9134
Gelissen, Ingrid https://orcid.org/0000-0002-3961-2288
Chan, Wai-Jo Jocelin https://orcid.org/0000-0002-2548-6030
Harnett, Joanna E. https://orcid.org/0000-0001-9904-2144
Funding

Funding for this research was provided by:

University of Sydney
License Information

Text and Data Mining valid from 2024-12-18

Version of Record valid from 2024-12-18
More Information

Article History

Received: 6 June 2024

Accepted: 9 December 2024

First Online: 18 December 2024

Declarations

:

: N/A.

: N/A.

: The corresponding author (I.C.) is a research student and a non-practising pharmacist who works in the pharmaceutical industry. She has no past or present affiliations with any pharmaceutical companies that manufacture or distribute cannabis-based products. She has not received any grants or payments related to any cannabis-based products.Authors JHu and JHar have received payments, travel and/or accommodation for providing expert advice about traditional, complementary and integrative medicine to industry, government bodies and non-government organisations. They have spoken at conferences and/or provided consultations for which honoraria, registration, travel and/or accommodation have been paid for by the organisers.Jennifer Hunter reports a relationship with Southern Cannabis Holdings (SCH) Research and NICM Health Research Institute, Western Sydney University that includes consulting fees.There are no competing interests associated with this publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below